Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis

  • Technology appraisal guidance
  • TA373
  • Published: 
Download guidance (PDF)

9 Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by the Southampton Health Technology Assessments Centre:

  • Shephard J, Cooper K, Harris P et al., The clinical and cost‑effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation, July 2015

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document. Organisations listed in I, II and III were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I. Companies:

  • AbbVie

  • Bristol‑Myers Squibb

  • Pfizer

  • Roche Products

II. Professional/expert and patient/carer groups:

  • British Society for Paediatric and Adolescent Rheumatology

  • National Rheumatoid Arthritis Society

  • Primary Care Rheumatology Society

  • Royal College of Paediatrics & Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

IV. Commentator organisations (without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on abatacept, adalimumab, etanercept and tocilizumab by attending the initial Committee discussion and/or providing a written statement to the Committee. They are invited to comment on the appraisal consultation document.

  • Dr Hana Alachkar, Consultant Immunologist, nominated by the Royal College of Pathologists – clinical expert

  • Dr Kate Armon, Consultant Paediatric Rheumatologist, nominated by the British Society for Paediatric and Adolescent Rheumatology – clinical expert

  • Helen Berger, nominated by the National Rheumatoid Arthritis Society – patient expert

  • Ailsa Bosworth, Chief Executive Office of the National Rheumatoid Arthritis Society, nominated by the National Rheumatoid Arthritis Society – patient expert

D. Representatives from the following companies attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • AbbVie

  • Bristol‑Myers Squibb

  • Pfizer

  • Roche Products